1
|
Vautrin M, Tombette F, Icard V, Leoz M, Trabaud MA, Ouziel A, Panetta L, Lemée V, Plantier JC, Moisan A. First evidence of a mother-to-child transmission of an HIV-1/MO intergroup recombinant form. Clin Microbiol Infect 2024; 30:691-693. [PMID: 38387501 DOI: 10.1016/j.cmi.2024.02.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 02/07/2024] [Accepted: 02/15/2024] [Indexed: 02/24/2024]
Affiliation(s)
- Manon Vautrin
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, F-76000 Rouen, France
| | - Fabienne Tombette
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France
| | - Vinca Icard
- Virology Department, Institut des Agents Infectieux, Hôpital de la Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France
| | - Marie Leoz
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, F-76000 Rouen, France
| | - Mary-Anne Trabaud
- Virology Department, Institut des Agents Infectieux, Hôpital de la Croix Rousse, Hospices Civils de Lyon, 69004 Lyon, France
| | - Antoine Ouziel
- Department of Pediatric Emergency & Pediatric Intensive Care, Hôpital Femme-Mère Enfant, Hospices Civils de Lyon, 69677 Bron cedex, France
| | - Luc Panetta
- Department of Pediatric Emergency & Pediatric Intensive Care, Hôpital Femme-Mère Enfant, Hospices Civils de Lyon, 69677 Bron cedex, France
| | - Véronique Lemée
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France
| | - Jean-Christophe Plantier
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France.
| | - Alice Moisan
- Univ Rouen Normandie, Université de Caen Normandie, INSERM, Normandie Univ, DYNAMICURE UMR 1311, CHU Rouen, Department of Virology, National Reference Center of HIV, F-76000 Rouen, France
| |
Collapse
|
2
|
Roy A, Saade C, Josset L, Clément B, Morfin F, Destras G, Valette M, Icard V, Billaud G, Oblette A, Debombourg M, Garrigou C, Brengel-Pesce K, Generenaz L, Saker K, Hernu R, Pozzetto B, Lina B, Trabaud MA, Trouillet-Assant S, Bal A. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients. J Med Virol 2023; 95:e28984. [PMID: 37503561 DOI: 10.1002/jmv.28984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Revised: 06/23/2023] [Accepted: 07/13/2023] [Indexed: 07/29/2023]
Abstract
We aimed to evaluate the association between the humoral and cellular immune responses and symptomatic SARS-CoV-2 infection with Delta or Omicron BA.1 variants in fully vaccinated outpatients. Anti-receptor binding domain (RBD) IgG levels and interferon-gamma (IFN-γ) release were evaluated at PCR-diagnosis of SARS-CoV-2 in 636 samples from negative and positive patients during Delta and Omicron BA.1 periods. Median levels of anti-RBD IgG in positive patients were significantly lower than in negative patients for both variants (p < 0.05). The frequency of Omicron BA.1 infection in patients with anti-RBD IgG concentrations ≥1000 binding antibody units (BAU)/mL was 51.0% and decreased to 34.4% in patients with concentrations ≥3000 BAU/mL. For Delta infection, the frequency of infection was significantly lower when applying the same anti-RBD IgG thresholds (13.3% and 5.3% respectively, p < 0.05). In addition, individuals in the hybrid immunity group had a 4.5 times lower risk of Delta infection compared to the homologous vaccination group (aOR = 0.22, 95% CI: [0.05-0.64]. No significant decrease in the risk of Omicron BA.1 infection was observed in the hybrid group compared to the homologous group, but the risk decreased within the hybrid group as anti-RBD IgG titers increased (aOR = 0.08, 95% CI: [0.01-0.41], p = 0.008). IFN-γ release post-SARS-CoV-2 peptide stimulation was not different between samples from patients infected (either with Delta or Omicron BA.1 variant) or not (p > 0.05). Our results show that high circulating levels of anti-RBD IgG and hybrid immunity were independently associated with a lower risk of symptomatic SARS-CoV-2 infection in outpatients with differences according to the infecting variant (www.clinicaltrials.gov; ID NCT05060939).
Collapse
Affiliation(s)
- Alvaro Roy
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- ECDC Fellowship Programme, Public Health Microbiology Path (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Solna, Sweden
| | - Carla Saade
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Laurence Josset
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| | - Bénédicte Clément
- Services des urgences, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Florence Morfin
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| | - Grégory Destras
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| | - Martine Valette
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
| | - Vinca Icard
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
| | - Geneviéve Billaud
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
| | - Antoine Oblette
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| | - Marion Debombourg
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Christine Garrigou
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
| | - Karen Brengel-Pesce
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Laurence Generenaz
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Kahina Saker
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Romain Hernu
- Services des urgences, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Bruno Pozzetto
- Team GIMAP, CIRI-Centre International de Recherche en Infectiologie, Université Jean Monnet de Saint-Etienne, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, Saint-Etienne, France
- Laboratoire des Agents Infectieux et d'Hygiène, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France
| | - Bruno Lina
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| | - Mary-Anne Trabaud
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
| | - Sophie Trouillet-Assant
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- Joint Research Unit Civils Hospices of Lyon-bioMérieux, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Antonin Bal
- Laboratoire de Virologie, Institut des Agents Infectieux, Centre National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, Lyon, France
- CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, Lyon, France
- GenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
3
|
Charre C, Lemoine S, Icard V, Maud R, Tardy JC, Chiarello P, Godinot M, Avettand-Fenoel V. HIV-1-Associated Kidney Disease in an Elite Controller. AIDS Patient Care STDS 2022; 36:413-415. [PMID: 36301263 DOI: 10.1089/apc.2022.0120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Caroline Charre
- Université Paris Cité, Faculté de Médecine, Paris, France.,INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France.,Department of Virology, Hôpital Cochin, APHP, Paris, France
| | - Sandrine Lemoine
- Université de Lyon, Lyon, France.,Department of Nephrology, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Vinca Icard
- Department of Virology, Institut de Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Rabeyrin Maud
- Department of Anatomical Pathology, Centre de Biologie et de Pathologie Grand Est, Hospices Civils de Lyon, Lyon, France
| | - Jean-Claude Tardy
- Department of Virology, Institut de Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Pierre Chiarello
- Department of Infectious Diseases, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Matthieu Godinot
- Department of Infectious Diseases, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Véronique Avettand-Fenoel
- Université Paris Cité, Faculté de Médecine, Paris, France.,INSERM U1016, CNRS UMR8104, Institut Cochin, Paris, France.,Department of Virology, Hôpital Cochin, APHP, Paris, France
| |
Collapse
|
4
|
Rahib D, Bercot B, Delagreverie H, Gabassi A, Delaugerre C, Salord H, Icard V, Le Thi TT, Leveau B, Khiri H, Digne J, Didelot MN, Pisoni A, Tuaillon E, Lydié N, Vandentorren S. Online self-sampling kits for human immunodeficiency virus and other sexually transmitted infections: Feasibility, positivity rates, and factors associated with infections in France. Int J STD AIDS 2022; 33:355-362. [PMID: 35144493 DOI: 10.1177/09564624211066447] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Men who have sex with men are increasingly diagnosed with sexually transmitted infections (STI) in France. To address this situation, quarterly screening for HIV combined with hepatitis B (HBV) and hepatitis C (HCV), as well as annual screening for C.trachomatis (CT) and N.gonorrhoeae (NG) are recommended. The MemoDepistages program offered an at-home screening solution for these infections. This study describes the feasibility of this screening process, the rate of positive test results, and the factors associated with positivity. METHODS Participants were recruited online. Laboratories verified the quantity and quality of the samples. Logistic regression was used to determine the associated factors for infection. RESULTS Overall, 1556 out of 1908 (81.6%) blood samples were tested for at least HIV. A total of eight participants (0.5%) were newly diagnosed with HIV and four with HCV (0.3%). No new infection was confirmed for HBV. Overall positivity was 9.3% for CT and 9.6% for NG. The highest positivity was reported in rectal swabs for CT (7.3%) and in pharyngeal swabs for NG (7.2%). Factors associated with extragenital CT/NG were age under 30 years (for pharyngeal and rectal infections) and having at least 10 partners in the past 6 months (p<0.001) (for pharyngeal infections only). CONCLUSIONS The self-sampling kit for multiple STIs can perform comprehensive tests and identify new infections in young people, especially in extragenital sites.
Collapse
Affiliation(s)
- Delphine Rahib
- 472516Santé Publique France, Saint Maurice, France.,Inserm, 243485Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), Université de Paris, Paris, France
| | - Béatrice Bercot
- Service de Bactériologie, 55663Hôpital St Louis, APHP, Inserm UMR1137, IAME, Université de Paris, Paris, France
| | - Héloïse Delagreverie
- Service de Virologie, 55663Hôpital St Louis, APHP, Inserm U944, Université de Paris, Paris, France
| | - Audrey Gabassi
- Service de Virologie, 55663Hôpital St Louis, APHP, Inserm U944, Université de Paris, Paris, France
| | - Constance Delaugerre
- Service de Virologie, 55663Hôpital St Louis, APHP, Inserm U944, Université de Paris, Paris, France
| | - Hélène Salord
- Hôpital de La Croix-Rousse, Centre de Ressources Biologiques Nord, 26900Hospices Civils de Lyon, Lyon, France
| | - Vinca Icard
- Hôpital de La Croix-Rousse, Centre de Ressources Biologiques Nord, 26900Hospices Civils de Lyon, Lyon, France
| | - Than-Thuy Le Thi
- Hôpital de La Croix-Rousse, Centre de Ressources Biologiques Nord, 26900Hospices Civils de Lyon, Lyon, France
| | - Benjamin Leveau
- Hôpital de La Croix-Rousse, Centre de Ressources Biologiques Nord, 26900Hospices Civils de Lyon, Lyon, France
| | | | | | - Marie-Noëlle Didelot
- Département de Bactériologie-Virologie, 26905CHU de Montpellier, UMR Inserm 1058, Université de Montpellier, Montpellier, France
| | - Amandine Pisoni
- Département de Bactériologie-Virologie, 26905CHU de Montpellier, UMR Inserm 1058, Université de Montpellier, Montpellier, France
| | - Edouard Tuaillon
- Département de Bactériologie-Virologie, 26905CHU de Montpellier, UMR Inserm 1058, Université de Montpellier, Montpellier, France
| | | | - Stéphanie Vandentorren
- 472516Santé Publique France, Saint Maurice, France.,Inserm, 243485Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), Université de Paris, Paris, France
| |
Collapse
|
5
|
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-Thiébaut C, Foltzer A, Bouiller K, Hustache-Mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-Storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-Dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-Fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-Degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-Dupont H, Poizot-Martin I, Brégigeon S, Zaegel-Faucher O, Obry-Roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-Rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-François S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-Garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-Keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-Pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-Tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le GAC S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-Laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, PaLich R, Blanc C, Katlama C, Bani-Sadr F, Berger JL, N’Guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-Delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-Vannier M, Jovelin T, Sinteff JP, Gagneux-Brunon A, Botelho-Nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-Henry C, de Mautort E, Fafi-Kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-Blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-Desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis 2021; 73:e3266-e3274. [DOI: 10.1093/cid/ciaa1940] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 01/01/2021] [Indexed: 01/15/2023] Open
Abstract
Abstract
Background
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort.
Methods
This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors.
Results
From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018.
Conclusions
A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.
Clinical Trials Registration. NCT02898987.
Collapse
Affiliation(s)
- Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Lyon, France
| | - Laurent Hocqueloux
- Department of Infectious Diseases, Centre Hospitalier Régional d’Orléans – La Source, Orléans, France
| | - Maeva Lefebvre
- Department of Infectious Diseases, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes; Centre d’Investigation Clinique (CIC) 1413, INSERM, Nantes, France
| | - Pierre Pradat
- Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Isabelle Poizot-Martin
- Immuno-Hematology Clinic, Assistance Publique–Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, Aix-MarseilleUniversity–Inserm–Institut de Recherche pour le Développement (IRD), Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l’Archet, Nice, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg
| | - André Cabié
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort de France, Université des Antilles EA4537, Fort de France, INSERM CIC1424, Fort-de-France, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Rahib D, Delagreverie H, Gabassi A, Le Thi TT, Vassel E, Vodosin P, Leveau B, Pisoni A, Tuaillon E, Digne J, Icard V, Delaugerre C, Lydié N. Online self-sampling kits to screen multipartner MSM for HIV and other STIs: participant characteristics and factors associated with kit use in the first 3 months of the MemoDepistages programme, France, 2018. Sex Transm Infect 2021; 97:134-140. [PMID: 33397802 DOI: 10.1136/sextrans-2020-054790] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 12/07/2020] [Accepted: 12/13/2020] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES In 2017, to reduce the proportion of men who have sex with men (MSM) in the undiagnosed HIV population in France (38%), HIV screening is advised each 3 months and STI screening is advised each year in multipartner MSM. Despite the range of testing solutions, over 40% of MSM were not tested for HIV and over 50% for STIs in the past year. Based on international experiments that offer screening solutions via online advertising, the French National Health Agency launched a programme (MemoDepistages) to provide a free self-sampling kit (SSK) for HIV and STIs. This article analyses the sociodemographic and behavioural characteristics of MSM in terms of kit acceptance and sample return. METHODS Participants were registered for the programme online after ordering an SSK. The study included men aged over 18 years, living in one of the four selected French regions, and willing to disclose their postal and email address; they had health insurance, acknowledged more than one male partner in the past year, indicated a seronegative or unknown HIV status and were not taking medically prescribed pre-exposure prophylaxis drugs. Samples were collected by users and posted directly to the laboratory. Characteristics associated with kit acceptance and sample return were analysed using logistic regression. RESULTS Overall, 7158 eligible MSM were offered to participate in the programme, with 3428 ordering the kit (47.9%) and 1948 returning their sample, leading to a return rate of 56.8% and an overall participation rate of 27.2%. Acceptance and return rates were strongly associated with sociodemographic characteristics, mainly education level but not with behavioural characteristics. Non-college graduates had lower acceptance (44.2%) and return rates (47.7%). CONCLUSION The programme rapidly recruited a large number of MSM. It removed geographical inequalities related to screening access.
Collapse
Affiliation(s)
- Delphine Rahib
- Sexual Health Unit, Santé publique France, Saint Maurice, France .,iPLESP UMRS1136, INSERM, Paris, France
| | | | - Audrey Gabassi
- Microbiology Department, Hopital Saint-Louis, Paris, France
| | - Thanh-Thuy Le Thi
- Centre de ressources biologiques Nord, Hospices Civils de Lyon, Lyon, France
| | - Eleonore Vassel
- Centre de ressources biologiques Nord, Hospices Civils de Lyon, Lyon, France
| | - Pierre Vodosin
- Centre de ressources biologiques Nord, Hospices Civils de Lyon, Lyon, France
| | - Benjamin Leveau
- Centre de ressources biologiques Nord, Hospices Civils de Lyon, Lyon, France
| | - Amandine Pisoni
- Département de bactériologie-virologie, Inserm UMR 1058, CHRU de Montpellier, Montpellier, France
| | - Edouard Tuaillon
- Département de bactériologie-virologie, Inserm UMR 1058, CHRU de Montpellier, Montpellier, France
| | | | - Vinca Icard
- Centre de ressources biologiques Nord, Hospices Civils de Lyon, Lyon, France
| | | | - Nathalie Lydié
- Sexual Health Unit, Santé publique France, Saint Maurice, France
| | | |
Collapse
|
7
|
Charre C, Icard V, Pradat P, Brochier C, Lina B, Chidiac C, Cotte L. Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users. AIDS 2020; 34:1765-1770. [PMID: 32889852 PMCID: PMC7493781 DOI: 10.1097/qad.0000000000002639] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2020] [Revised: 06/19/2020] [Accepted: 07/03/2020] [Indexed: 01/08/2023]
Abstract
OBJECTIVE A new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) emerged in China during late 2019 and resulted in the coronavirus disease 2019 (COVID-19) pandemic which peaked in France in March-April 2020. Immunodeficiency, precariousness and promiscuity could increase the risk of COVID-19 in HIV-infected patients and in preexposure prophylaxis (PrEP) users. No epidemiological data are available in these two populations. We report COVID-19 attack rate in HIV-infected patients and in PrEP users in the Rhône department, France, and compared it with the general population. DESIGN Retrospective analysis of a laboratory database. METHODS COVID-19 testing strategy in France was centered on symptomatic infections, hospitalized patients and symptomatic healthcare workers while most asymptomatic cases were not confirmed. SARS-CoV-2 positivity rate on PCR assays and COVID-19 attack rate were determined in HIV-infected patients and in PrEP users. COVID-19 attack rate in the general population was estimated from health authorities' database and demographic data. A corrected attack rate taking into account the laboratory representativeness was calculated. RESULTS From March to April 2020, 24 860 samples from 19 113 patients (HIV-infected 77, PrEP users 27, others 19 009) were assessed for SARS-CoV-2 PCR assay. The positivity rate appeared similar in HIV-infected patients (15.6%), in PrEP users (14.8%) and in other patients (19.1%). The crude/corrected COVID-19 attack rate appeared similar in HIV-infected patients (0.31/0.38%) and in PrEP users (0.38/0.42%), and of the same order as the estimated attack rate in the general population (0.24%). CONCLUSION The risk of symptomatic COVID-19 in France appeared similar in HIV-infected patients and in PrEP users compared with the general population.
Collapse
Affiliation(s)
- Caroline Charre
- Laboratoire de Virologie, Institut de Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon
- Université́ Claude Bernard
- INSERM U1052-CRCL (Centre de Recherche en Cancérologie)
| | - Vinca Icard
- Laboratoire de Virologie, Institut de Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon
| | - Pierre Pradat
- Centre de Recherche Clinique (CRC), Hospices Civils de Lyon
| | | | - Bruno Lina
- Laboratoire de Virologie, Institut de Agents Infectieux, Centre National de Référence des Virus des Infections Respiratoires, Hôpital de la Croix-Rousse, Hospices Civils de Lyon
- Université́ Claude Bernard
| | - Christian Chidiac
- Université́ Claude Bernard
- Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| | - Laurent Cotte
- Service des Maladies Infectieuses et Tropicales, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
8
|
Trabaud MA, Icard V, Milon MP, Bal A, Lina B, Escuret V. Comparison of eight commercial, high-throughput, automated or ELISA assays detecting SARS-CoV-2 IgG or total antibody. J Clin Virol 2020; 132:104613. [PMID: 32942137 PMCID: PMC7476603 DOI: 10.1016/j.jcv.2020.104613] [Citation(s) in RCA: 43] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2020] [Accepted: 08/24/2020] [Indexed: 11/30/2022]
Abstract
8 commercial assays detecting similar class of SARS-CoV-2 -specific antibodies. Discrepancies found not linked to sensitivity, target Ag, total vs IgG antibodies. False negative results possible in pauci-symptomatic subjects.
Background Many commercial assays, of different designs, detecting SARS-CoV-2-specific antibodies exist but with little experience with them. Objectives The aim of this study was to compare the performance of assays detecting IgG or total antibodies to N or S antigens, validated for routine use in France, with samples from subjects with more or less severe SARS-CoV-2 infection. Methods Eight assays were used: Abbott Architect, DiaSorin Liaison®, bioMérieux Vidas®, Roche Elecsys Cobas®, Siemens Atellica®, BioRad Platelia ELISA, Epitope Diagnostics ELISA, and Wantai ELISA. The tested population included 86 samples from 40 hospitalized subjects and 28 outpatients at different time from symptom onset. Results The positivity rate varied depending on the assay but was greater for all assays in hospitalized than non-hospitalized patients. Despite a good correlation between the assays, discrepancies occurred, without a systematic origin, even for samples taken more than 20 days after symptom onset. These discrepancies were linked to low antibody levels in pauci-symptomatic patients. Conclusion Whichever assay is chosen, a false negative result may need to be ruled out with another test in a risk situation.
Collapse
Affiliation(s)
- Mary-Anne Trabaud
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.
| | - Vinca Icard
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Marie-Paule Milon
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Antonin Bal
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre National de Référence des Virus des Infections respiratoires (dont la grippe), Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - Bruno Lina
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre National de Référence des Virus des Infections respiratoires (dont la grippe), Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| | - Vanessa Escuret
- Laboratoire de Virologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Centre National de Référence des Virus des Infections respiratoires (dont la grippe), Hospices Civils de Lyon, Lyon, France; Université Lyon 1, Faculté de Médecine Lyon Est, CIRI, Inserm U1111 CNRS UMR5308, Virpath, Lyon, France
| |
Collapse
|
9
|
Charre C, Icard V, Trabaud MA, Tardy JC, Bouhour D. A case of acute multidrug resistant HIV-1 infection with acquired immunodeficiency syndrome. J Virus Erad 2018. [DOI: 10.1016/s2055-6640(20)30391-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Trabaud MA, Icard V, Ramière C, Tardy JC, Scholtes C, André P. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples. J Med Virol 2017; 89:1912-1919. [PMID: 28590068 DOI: 10.1002/jmv.24872] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Accepted: 05/24/2017] [Indexed: 11/06/2022]
Abstract
Sanger population sequencing (SPS) is the reference technique to monitor HIV-1-infected patients' therapy. Ultra-deep sequencing (UDS), which allows quantitative detection of drug resistance mutations, may be an alternative method. The study aimed to compare reproducibility and predictions of UDS versus SPS in a routine setting. A control containing low-abundance variants was repeatedly tested and clinical plasma samples from 100 patients were prospectively assayed by SPS and UDS using the Roche 454 system. Complete analysis by UDS was available for 88% of samples with various viral loads and subtypes. Comparison of detection thresholds found that SPS sensitivity was variable. Variations found by UDS between 5% to >20% were detected by SPS in 25% to more than 80% of samples. At the 5% cut-off, disagreements were rare and in most cases UDS detected an additional protease secondary mutation, suggesting a possible resistance to a protease inhibitor according to the 2015 ANRS algorithm. Mutations found on reverse transcriptase by only UDS were often explained by previous therapy. UDS with a variant detection threshold at 5% might allow therapy management with minimal differences compared to population sequencing while providing additional information for further determination of pertinent cutoff values for specific resistance mutations.
Collapse
Affiliation(s)
- Mary-Anne Trabaud
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France
| | - Vinca Icard
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France
| | - Christophe Ramière
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France.,Centre International de Recherche en Infectiologie (CIRI) (Inserm U1111, CNRS UMR 5308), Lyon, F-69007, France.,Ecole Normale Supérieure de Lyon, Lyon, F-69007, France.,Université Claude Bernard Lyon 1, Villeurbanne, F-69100, France
| | - Jean-Claude Tardy
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France
| | - Caroline Scholtes
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France.,Centre International de Recherche en Infectiologie (CIRI) (Inserm U1111, CNRS UMR 5308), Lyon, F-69007, France.,Ecole Normale Supérieure de Lyon, Lyon, F-69007, France.,Université Claude Bernard Lyon 1, Villeurbanne, F-69100, France
| | - Patrice André
- Laboratoire de Virologie, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, F-69004, France.,Centre International de Recherche en Infectiologie (CIRI) (Inserm U1111, CNRS UMR 5308), Lyon, F-69007, France.,Ecole Normale Supérieure de Lyon, Lyon, F-69007, France.,Université Claude Bernard Lyon 1, Villeurbanne, F-69100, France
| |
Collapse
|
11
|
Llagonne-Barets M, Icard V, Leparc-Goffart I, Prat C, Perpoint T, André P, Ramière C. A case of Mayaro virus infection imported from French Guiana. J Clin Virol 2016; 77:66-8. [PMID: 26921736 DOI: 10.1016/j.jcv.2016.02.013] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Revised: 01/19/2016] [Accepted: 02/16/2016] [Indexed: 11/15/2022]
Abstract
Emergence of arboviruses is a rising problem in several areas in the world. Here we report a case of Mayaro virus infection that was diagnosed in a French citizen presenting a dengue-like syndrome with prolonged arthralgia following a travel in French Guiana. Diagnosis was based on serological testing, a newly developed specific RT-PCR and sequencing. The real incidence of this viral infection among travelers is poorly known but this case is the first reported in a European area where Aedes albopictus mosquitoes are established, which underscores the necessity to determine the vector competence of the European strain of this mosquito species for Mayaro virus.
Collapse
Affiliation(s)
- Marion Llagonne-Barets
- Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France
| | - Vinca Icard
- Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | | | - Christine Prat
- Centre national de référence Arbovirus, IRBA, Marseille, France
| | - Thomas Perpoint
- Service de Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - Patrice André
- Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; CIRI, International Center for Infectiology Research, Université de Lyon, Lyon, France
| | - Christophe Ramière
- Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Lyon, France; CIRI, International Center for Infectiology Research, Université de Lyon, Lyon, France.
| |
Collapse
|
12
|
Saison J, Ferry T, Demaret J, Maucort Boulch D, Venet F, Perpoint T, Ader F, Icard V, Chidiac C, Monneret G. Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol 2014; 176:401-9. [PMID: 24460818 DOI: 10.1111/cei.12278] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2014] [Indexed: 01/07/2023] Open
Abstract
The mechanisms sustaining the absence of complete immune recovery in HIV-infected patients upon long-term effective highly active anti-retroviral therapy (HAART) remain elusive. Immune activation, regulatory T cells (T(regs)) or very low-level viraemia (VLLV) have been alternatively suspected, but rarely investigated simultaneously. We performed a cross-sectional study in HIV-infected aviraemic subjects (mean duration of HAART: 12 years) to concomitantly assess parameters associated independently with inadequate immunological response. Patients were classified as complete immunological responders (cIR, n = 48) and inadequate immunological responders (iIR, n = 39), depending on the CD4(+) T cell count (> or < 500/mm(3)). Clinical and virological data (including very low-level viraemia) were collected. In parallel, immunophenotyping of CD4(+) lymphocytes, including T(reg) subsets, and CD8(+) T cells was performed. Percentages of activated CD4(+) T cells, T(regs), effector T(regs) and terminal effector T(regs) were found to be significantly elevated in iIR. Neither the percentage of activated CD8(+) T cells nor VLLV were found to be associated with iIR. In the multivariate analysis, nadir of CD4(+) T cell count and percentage of T(regs) were the only two parameters associated independently with iIR [odds ratio (OR) = 2·339, P = 0·001, and OR = 0·803, P = 0·041]. We present here the largest study investigating simultaneously the immune response to long-term HAART, activation of CD4(+) and CD8(+) T cells, T(reg) percentages and very low-level viraemia. Causative interactions between T(regs) and CD4(+) T cells should now be explored prospectively in a large patients cohort.
Collapse
Affiliation(s)
- J Saison
- Immunology Laboratory, E. Herriot Hospital, Lyon, France; Infectious and Tropical Disease Unit, Croix Rousse Hospital, Lyon, France; Lyon-1 University, Lyon, France; CIRI (Centre International de Recherche en Infectiologie), Lyon, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Saison J, Ferry T, Demaret J, Ader F, Icard V, Chidiac C, Monneret G. A-14: Association entre réponse immunologique discordante, Tregs, activation immune et virémie résiduelle chez les patients infectés par le VIH. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70097-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Saison J, Tardy JC, Scholtes C, Icard V, Trabaud MA, Perpoint T, Chidiac C, Ecochard R, André P, Ferry T. Low-level viremia is associated with non-B subtypes in patients infected with HIV with virological success following HAART introduction. J Med Virol 2013; 85:953-8. [PMID: 23588720 DOI: 10.1002/jmv.23553] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/14/2013] [Indexed: 12/14/2022]
Abstract
This prospective study aimed to determine factors associated with detection of very low-level viremia in patients infected with HIV-1 with virological success following HAART introduction. Fifty-seven patients, mostly (n = 51, 89%) treated with a protease inhibitor-based regimen, were included and followed for 2 years. Viral loads were monitored by Abbott m2000 RealTime HIV-1. Patients were classified as (i) HIV-RNA-negative if viral loads remained strictly undetectable (0 copies/ml), or (ii) HIV-RNA-positive if at least one HIV-1 RNA could be detected in 1-49 copies/ml during follow-up. At month 24, 44 patients (77%) were in the HIV-RNA-positive group, whereas 13 (23%) remained without very low-level viremia. Univariate analysis, Kaplan-Meier curves and the Cox proportional hazard model revealed that B subtype was the only predictor of belonging to the HIV-RNA-negative group (HR 3.98; 95% CI 1.08-14.7). This association needs to be confirmed. Further study of the reservoir and the mechanisms of viral latency according to HIV-subtype will also be necessary to develop new therapeutic strategies and eradicate HIV infection.
Collapse
Affiliation(s)
- Julien Saison
- Virology Laboratory, Croix-Rousse Hospital, HCL, Lyon, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Trabaud MA, Icard V, Scholtes C, Perpoint T, Koffi J, Cotte L, Makhloufi D, Tardy JC, André P. Discordance in HIV-1 co-receptor use prediction by different genotypic algorithms and phenotype assay: intermediate profile in relation to concordant predictions. J Med Virol 2012; 84:402-13. [PMID: 22246825 DOI: 10.1002/jmv.23209] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Concordant and discordant genotypic predictions of HIV-1 co-receptor tropism were analyzed. V3 region was sequenced from plasma samples of patients screened for R5 tropism by the Trofile® assay, before CCR5 antagonist prescription. Ten tools including geno2pheno, PSSM, an "11/25" and "net charge" rule, and other published algorithms were used. Patients were grouped according to concordance or discordance between tools and Trofile® result. Trofile® tropism reports from 50 patient samples were R5 in 38 and Dual/Mixed (DM) in 12. Prediction with the genotypic tools were concordant for 23 R5 samples, and discordant for the 15 other ones. From Trofile® DM strains were concordant in 6 and discordant in 6. V3 sequences were not clearly distinct between R5 and DM strains, except a greater diversity in the later. Discordances were found with any tool or combination of them, so that no one can be proposed as better than the others. Predictive values of each algorithm were similar and rather good (efficacy ranged from 74% to 84%), but the rate of non-confirmed prediction is greater when compelling the results of all tools with each individual sample. The mean of quantitative values obtained with one tool when another tool give the opposite prediction were different from those obtained when all tools agree with that prediction. The two discordant groups were often not distinguishable from each other. These results suggest that viruses giving discordant prediction with bioinformatic tools could be functionally distinct and/or in a different evolutionary state compared to those with concordant prediction.
Collapse
Affiliation(s)
- Mary-Anne Trabaud
- Laboratory of Virology, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Pécheur EI, Diaz O, Molle J, Icard V, Bonnafous P, Lambert O, André P. Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis C virus glycoproteins. J Biol Chem 2010; 285:25802-11. [PMID: 20551330 DOI: 10.1074/jbc.m110.131664] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
The density of hepatitis C virus (HCV) particles circulating in the blood of chronically infected patients and of cell-culture produced HCV is heterogeneous. Specific infectivity and fusion of low density particles are higher than those of high density particles. We recently characterized hybrid particles produced by Caco-2 colon or Huh-7.5 liver cells transduced with HCV E1 and E2 envelope glycoproteins. Caco-2-derived particles, called empty lipo-viral particles (eLVP), are composed of triglyceride-rich lipoproteins positive for apolipoproteins B (i.e. apoB100 and apoB48) and contain HCV E1 and E2. Here we aimed at characterizing the morphology and in vitro fusion properties of eLVP using electron microscopy and fluorescence spectroscopy. They displayed the aspect of beta-lipoproteins, and immunogold labeling confirmed the presence of apoB and HCV E1 and E2 at their surface. These particles are able to fuse with lipid bilayers (liposomes) in a fusion process leading to the coalescence of internal contents of triglyceride-rich lipoproteins particles and liposomes. Fusion was pH-dependent and could be inhibited by either Z-fFG, a peptide known to inhibit viral fusion, or by monoclonal antibodies directed against HCV E2 or the apolipoprotein moiety of the hybrid particle. Interestingly, particles derived from Huh-7.5 cells failed to display equivalent efficient fusion. Optimal fusion activity is, thus, observed when HCV envelope proteins are associated to apoB-positive hybrid particles. Our results, therefore, point to a crucial role of the E1 and E2 proteins in HCV fusion with a subtle interplay with the apolipoprotein part of eLVP.
Collapse
Affiliation(s)
- Eve-Isabelle Pécheur
- Institut de Biologie et Chimie des Protéines, UMR CNRS 5086, Université Lyon 1, IFR128 Lyon BioSciences Gerland, 69007 Lyon, France.
| | | | | | | | | | | | | |
Collapse
|
17
|
Icard V, Diaz O, Scholtes C, Perrin-Cocon L, Ramière C, Bartenschlager R, Penin F, Lotteau V, André P. Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One 2009; 4:e4233. [PMID: 19156195 PMCID: PMC2617766 DOI: 10.1371/journal.pone.0004233] [Citation(s) in RCA: 111] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2008] [Accepted: 12/03/2008] [Indexed: 01/07/2023] Open
Abstract
The density of circulating hepatitis C virus (HCV) particles in the blood of chronically infected patients is very heterogeneous. The very low density of some particles has been attributed to an association of the virus with apolipoprotein B (apoB) positive and triglyceride rich lipoproteins (TRL) likely resulting in hybrid lipoproteins known as lipo-viro-particles (LVP) containing the viral envelope glycoproteins E1 and E2, capsid and viral RNA. The specific infectivity of these particles has been shown to be higher than the infectivity of particles of higher density. The nature of the association of HCV particles with lipoproteins remains elusive and the role of apolipoproteins in the synthesis and assembly of the viral particles is unknown. The human intestinal Caco-2 cell line differentiates in vitro into polarized and apoB secreting cells during asymmetric culture on porous filters. By using this cell culture system, cells stably expressing E1 and E2 secreted the glycoproteins into the basal culture medium after one week of differentiation concomitantly with TRL secretion. Secreted glycoproteins were only detected in apoB containing density fractions. The E1-E2 and apoB containing particles were unique complexes bearing the envelope glycoproteins at their surface since apoB could be co-immunoprecipitated with E2-specific antibodies. Envelope protein secretion was reduced by inhibiting the lipidation of apoB with an inhibitor of the microsomal triglyceride transfer protein. HCV glycoproteins were similarly secreted in association with TRL from the human liver cell line HepG2 but not by Huh-7 and Huh-7.5 hepatoma cells that proved deficient for lipoprotein assembly. These data indicate that HCV envelope glycoproteins have the intrinsic capacity to utilize apoB synthesis and lipoprotein assembly machinery even in the absence of the other HCV proteins. A model for LVP assembly is proposed.
Collapse
Affiliation(s)
- Vinca Icard
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
- Hospices Civils de Lyon, Laboratoire de Virologie Nord, Lyon, France
| | - Olivier Diaz
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
| | - Caroline Scholtes
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
- Hospices Civils de Lyon, Laboratoire de Virologie Nord, Lyon, France
| | - Laure Perrin-Cocon
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
| | - Christophe Ramière
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
- Hospices Civils de Lyon, Laboratoire de Virologie Nord, Lyon, France
| | - Ralf Bartenschlager
- Department of Molecular Virology, University of Heidelberg, Heidelberg, Germany
| | - Francois Penin
- CNRS, UMR 5086, Institut de Biologie et Chimie des Protéines, Lyon, France
| | - Vincent Lotteau
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
- Hospices Civils de Lyon, Laboratoire de Virologie Nord, Lyon, France
| | - Patrice André
- Université de Lyon, Lyon, France
- Inserm, U851, Lyon, France
- Université de Lyon1, IFR128 BioSciences Lyon-Gerland, Lyon, France
- Hospices Civils de Lyon, Laboratoire de Virologie Nord, Lyon, France
- * E-mail:
| |
Collapse
|
18
|
Diaz O, Cubero M, Trabaud MA, Quer J, Icard V, Esteban JI, Lotteau V, André P. Transmission of low-density hepatitis C viral particles during sexually transmitted acute resolving infection. J Med Virol 2008; 80:242-6. [PMID: 18098146 DOI: 10.1002/jmv.21037] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Hepatitis C viruses in the blood of chronically infected patients are heterogeneous in density with the presence of lipoprotein associated viral particles of lower density than conventional virions. If low-density viral particles have been shown to be infectious in animal models it is currently not known whether these particles display the same infectivity for humans. In a case of sexually transmitted acute resolving infection, all isolated NS3 sequences from the acute-phase isolate clustered with a single sequence from the chronic carrier isolate, suggesting bottlenecking during transmission. To determine the density of the transmitted viruses, viral quasispecies from fractions with density below and above 1.055 g/ml were isolated and prepared from the plasma of the chronically infected sexual partner. Interestingly, the three closest sequences to the recipient consensus sequence were isolated from the low-density fraction. These data suggest that low-density viral particles are infectious for humans as they are for chimpanzees and that they can be transmitted during sexual intercourse.
Collapse
|
19
|
Trabaud MA, Cotte L, Labernardière JL, Lebel-Binay S, Icard V, Tardy JC, Trepo C, Andre P. Variants With Different Mutation Patterns Persist in the Quasispecies of Enfuvirtide-Resistant HIV-1 Population During and After Treatment In Vivo. J Acquir Immune Defic Syndr 2007; 46:134-44. [PMID: 17621239 DOI: 10.1097/qai.0b013e3181354710] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Genotypic and phenotypic resistance in 11 HIV-1-infected patients receiving enfuvirtide (ENF), as part of a salvage regimen, has been evaluated. METHODS Resistance mutations were detected by sequencing the gp41 ectodomain from plasma samples. During treatment, longitudinal samples from 1 patient were sequenced after limiting dilution of complementary DNA to isolate single genomes. Phenotypic resistance was evaluated with a new recombinant virus assay (PHENOSCRIPT; VIRalliance, Paris, France), allowing the determination of coreceptor use. RESULTS All patients experienced ENF failure. One to 4 mutations in the 36-to-45 gp41 region appeared during ENF therapy in all patients and disappeared after ENF removal. Mixtures of wild type and mutants unexpectedly persisted under ENF treatment, however, despite continued replication, leading to discordant results between genotypic and phenotypic data. Sequencing of isolated genomes from 1 patient confirmed that a wild-type first heptad repeat region (HR1) region was still present at the end of therapy. Several mutated variants coexisted at different time points, despite a tendency toward quasispecies reduction with time. CONCLUSION Individual variability of the mutation pattern and persistence of strains without mutation in the region mainly targeted by ENF resistance probably reflect the fact that resistance to ENF may rely on regions of gp41 or gp120 other than residues 36 to 45.
Collapse
|